Anticoagulant News and Research

RSS

Differences in patient education level may compromise safety, efficacy of anticoagulants

Patients with no schooling benefit least from blood thinning medications, reveals a European Heart Rhythm Association / European Society of Cardiology survey published today in Europace.

22 Feb 2016

Tick genome study sheds light on occurrences of Lyme disease

After a decade-long research effort the genome of the deer tick has been sequenced by an international team of scientists, including researchers from the SIB Swiss Institute of Bioinformatics.

12 Feb 2016

New blood clotting analysis system could help determine effects antithrombotic (anti-clotting) drugs

A new blood clotting analysis system designed in Japan makes it easier to determine the effects of taking one or more antithrombotic (anti-clotting) drugs.

29 Jan 2016

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia.

22 Jan 2016

Middle-aged patients undergoing AVR may fare better with tissue-based valves rather than metal-based valves

Patients between the ages of 40 and 70 who undergo aortic valve replacement (AVR) may fare better with tissue-based valves rather than metal-based valves, according to a review article posted online today by The Annals of Thoracic Surgery.

13 Jan 2016

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients.

7 Jan 2016

MUSC researchers receive PCORI grant to study safety, effectiveness of three blood-thinning drugs

A research team at the Medical University of South Carolina has been approved for a $13.5 million funding award by the Patient-Centered Outcomes Research Institute to study the safety and effectiveness of three blood-thinning drugs used to prevent potentially deadly blood clots in patients undergoing hip and knee replacement.

5 Jan 2016

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding.

23 Dec 2015

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

The American College of Cardiology has launched a new STS/ACC TAVR In-Hospital Mortality Risk App and an extensively overhauled the ACC AnticoagEvaluator App, bolstering its expansive Clinical App Collection. With these new and improved apps, the ACC continues to diversify the clinical content and decision support it offers clinicians in the mobile space.

22 Dec 2015

Poor outlook for ICH associated with novel oral anticoagulants

Haematoma expansion, disability and death are common among patients who have intracerebral haemorrhage while taking novel oral anticoagulants, a study in JAMA Neurology shows.

18 Dec 2015

Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published online in the Journal of the American College of Surgeons ahead of print publication early next year.

16 Dec 2015

Merus reports revenues of $49.0 million for fiscal 2015

Merus Labs International Inc. is pleased to report its financial results for fiscal year ending September 30, 2015.

7 Dec 2015

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research.

7 Dec 2015

Older patients can recover from acute subdural hematomas

According to a study completed at the Helsinki University Hospital Department of Neurosurgery, even patients over the age of 75 may recover from severe traumatic brain injury. This is the first study to describe the results of surgically treated elderly patients with acute subdural hematomas.

27 Nov 2015

Columbia University data scientists create world's first catalog of therapeutic venom

What doesn't kill you could cure you. A growing interest in the therapeutic value of animal venom has led a pair of Columbia University data scientists to create the first catalog of known animal toxins and their physiological effects on humans.

26 Nov 2015

New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

Medical Compression Systems, Inc. (MCS), today announced new data further validating the use of the ActiveCare DVT prophylaxis compression system following total joint replacement procedures.

11 Nov 2015

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

10 Nov 2015

Screening for asymptomatic atrial fibrillation could reduce risk of stroke, premature death

Screening for asymptomatic atrial fibrillation (AF) in people aged 65 and over and treating it with anticoagulant medications could greatly reduce the risk of stroke and premature death, say cardiologists in today's Journal of the American Medical Association.

10 Nov 2015

Nanofiber hydrogel infused with snake venom may stop bleeding, protect wounds

A nanofiber hydrogel infused with snake venom may be the best material to stop bleeding quickly, according to Rice University scientists.

27 Oct 2015

The American Heart Association and Heart Rhythm Society Unite to Improve Cardiovascular Research, Care

The American Heart Association and Heart Rhythm Society today announced a collaboration designed to advance research and improve the delivery of care for people with an irregular heartbeat known as atrial fibrillation (AFib).

20 Oct 2015